



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

3rd September 2024

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received a Corrigendum dated 2nd September 2024 to Order dated 30th August 2024 from Tamil Nadu GST authorities for the FY 2019-20. The relevant details to be disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Deputy Commissioner, Poonamallee Division – Chennai
2	Nature and details of the action(s) taken, initiated or order(s) passed	Corrigendum date 2 nd September 2024 to Order dated 30 th August 2024 passed under Section 73 of CGST Act, 2017 for the FY 2019-20 The amount of penalty as per the Order dated 30 th August 2024 was INR 13,11,299. The same has been increased to INR 18,63,920 vide the above Corrigendum dated 2 nd September 2024
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	2 nd September 2024
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has disallowed certain GST credit and raised GST demand for FY 2019-20 on account of difference in GST credit mismatch between Company's GST returns and details reported by vendors in their GST returns.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on financial operations of the Company. The Company believes that the said demand is not maintainable and will be filing an Appeal against the said Order

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151